• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

教育水平对多发性骨髓瘤患者生存的预测作用。

Education level as a predictor of survival in patients with multiple myeloma.

机构信息

Department of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.

Department of Hematology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.

出版信息

BMC Cancer. 2020 Aug 8;20(1):737. doi: 10.1186/s12885-020-07178-5.

DOI:10.1186/s12885-020-07178-5
PMID:32770980
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7414648/
Abstract

BACKGROUND

Disparities in multiple myeloma (MM) prognosis based on sociodemographic factors may exist. We investigated whether education level at diagnosis influenced Chinese MM patient outcomes.

METHODS

We performed a multicenter retrospective analysis of data from 773 MM patients across 9 centers in China from 2006 to 2019. Sociodemographic and clinical factors at diagnosis and treatment regimens were recorded, and univariate and multivariate analyses were performed.

RESULTS

Overall, 69.2% of patients had low education levels. Patients with low education levels differed from those with high education levels in that they were more likely to be older, and a higher proportion lived in rural areas, were unemployed, had lower annual incomes and lacked insurance. Additionally, compared to patients with high education levels, patients with low education levels had a higher proportion of international staging system (ISS) stage III classification and elevated lactate dehydrogenase (LDH) levels and underwent transplantation less often. Patients with high education levels had a median progression-free survival (PFS) of 67.50 (95% confidence interval (CI): 51.66-83.39) months, which was better than that of patients with low education levels (30.60 months, 95% CI: 27.38-33.82, p < 0.001). Similarly, patients with high education levels had a median overall survival (OS) of 122.27 (95% CI: 117.05-127.49) months, which was also better than that of patients with low education levels (58.83 months, 95% CI: 48.87-62.79, p < 0.001). In the multivariable analysis, patients with high education levels had lower relapse rates and higher survival rates than did those with low education level in terms of PFS and OS (hazard ratio (HR) = 0.50 [95% CI: 0.34-0.72], p < 0.001; HR = 0.32 [0.19-0.56], p < 0.001, respectively).

CONCLUSIONS

Low education levels may independently predict poor survival in MM patients in China.

摘要

背景

多发性骨髓瘤(MM)的预后可能因社会人口因素而存在差异。我们研究了诊断时的教育水平是否会影响中国 MM 患者的结局。

方法

我们对 2006 年至 2019 年期间来自中国 9 个中心的 773 名 MM 患者的数据进行了多中心回顾性分析。记录了诊断时的社会人口学和临床因素以及治疗方案,并进行了单因素和多因素分析。

结果

总体而言,69.2%的患者受教育程度较低。与受教育程度较高的患者相比,受教育程度较低的患者年龄更大,农村地区居住比例更高,失业比例更高,年收入较低,缺乏保险。此外,与受教育程度较高的患者相比,受教育程度较低的患者国际分期系统(ISS)分期 III 级分类比例较高,乳酸脱氢酶(LDH)水平升高,移植比例较低。受教育程度较高的患者无进展生存期(PFS)的中位数为 67.50(95%置信区间(CI):51.66-83.39)个月,优于受教育程度较低的患者(30.60 个月,95%CI:27.38-33.82,p<0.001)。同样,受教育程度较高的患者总生存期(OS)的中位数为 122.27(95%CI:117.05-127.49)个月,也优于受教育程度较低的患者(58.83 个月,95%CI:48.87-62.79,p<0.001)。在多变量分析中,与受教育程度较低的患者相比,受教育程度较高的患者 PFS 和 OS 的复发率较低,生存率较高(风险比(HR)=0.50[95%CI:0.34-0.72],p<0.001;HR=0.32[0.19-0.56],p<0.001)。

结论

在中国,低教育水平可能独立预测 MM 患者的不良预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f015/7414648/d58ae5509f5c/12885_2020_7178_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f015/7414648/d58ae5509f5c/12885_2020_7178_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f015/7414648/d58ae5509f5c/12885_2020_7178_Fig1_HTML.jpg

相似文献

1
Education level as a predictor of survival in patients with multiple myeloma.教育水平对多发性骨髓瘤患者生存的预测作用。
BMC Cancer. 2020 Aug 8;20(1):737. doi: 10.1186/s12885-020-07178-5.
2
High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma.高血清乳酸脱氢酶预示中国老年多发性骨髓瘤患者预后不良。
Oncotarget. 2017 Jul 18;8(29):48350-48361. doi: 10.18632/oncotarget.16237.
3
High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.高血清乳酸脱氢酶水平即使在新型药物治疗时代,也为国际骨髓瘤分期系统增加了预后价值。
Eur J Haematol. 2010 Aug;85(2):114-9. doi: 10.1111/j.1600-0609.2010.01466.x. Epub 2010 May 6.
4
Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.骨骼和软组织浆细胞瘤骨髓瘤患者自体干细胞移植后的结局比较。
Eur J Haematol. 2014 Nov;93(5):414-21. doi: 10.1111/ejh.12377. Epub 2014 Jun 14.
5
High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma.高血清乳酸脱氢酶水平作为多发性骨髓瘤耐药和生存期短的标志物
Ann Intern Med. 1991 Dec 15;115(12):931-5. doi: 10.7326/0003-4819-115-12-931.
6
LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.在接受基于硼替佐米的诱导方案且适合移植的骨髓瘤患者中,乳酸脱氢酶(LDH)是一个独立于国际分期系统(ISS)的不良预后因素。
Eur J Haematol. 2015 Apr;94(4):330-5. doi: 10.1111/ejh.12434. Epub 2014 Oct 18.
7
Multiple myeloma in elderly patients: prognostic factors and outcome.老年患者的多发性骨髓瘤:预后因素与结局
Eur J Haematol. 2005 Nov;75(5):370-5. doi: 10.1111/j.1600-0609.2005.00532.x.
8
Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.修订后的国际分期系统对新诊断多发性骨髓瘤自体移植后早期复发(<24 个月)具有预测和预后价值。
Biol Blood Marrow Transplant. 2019 Apr;25(4):683-688. doi: 10.1016/j.bbmt.2018.12.141. Epub 2018 Dec 21.
9
Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.输注淋巴细胞剂量越高,淋巴细胞恢复情况越好,而这反过来又预示着多发性骨髓瘤患者自体造血干细胞移植后的总生存期更长。
Biol Blood Marrow Transplant. 2008 Jan;14(1):116-24. doi: 10.1016/j.bbmt.2007.08.051.
10
Serum Lactate Dehydrogenase Can Be Used as a Factor for Re-Evaluating First-Relapsed Multiple Myeloma.血清乳酸脱氢酶可作为重新评估初发多发性骨髓瘤复发的一个因素。
Acta Haematol. 2020;143(6):559-566. doi: 10.1159/000505737. Epub 2020 Jul 1.

引用本文的文献

1
Income and education affect prognosis and treatment in symptomatic myeloma : A population-based study on 8672 multiple myeloma patients diagnosed 2008-2021 from the Swedish myeloma registry.收入和教育程度影响有症状骨髓瘤的预后和治疗:一项基于人群的研究,研究对象为2008年至2021年从瑞典骨髓瘤登记处确诊的8672例多发性骨髓瘤患者。
Ann Hematol. 2025 Jan;104(1):565-572. doi: 10.1007/s00277-025-06214-3. Epub 2025 Jan 24.
2
Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM.448 例新诊断多发性骨髓瘤患者接受硼替佐米为基础的诱导治疗的预后因素:ASCT、移植拒绝和高危 MM 的影响。
Bone Marrow Transplant. 2024 May;59(5):660-669. doi: 10.1038/s41409-024-02227-0. Epub 2024 Feb 21.
3

本文引用的文献

1
Impact of age, sex, ethnicity, socio-economic deprivation and novel pharmaceuticals on the overall survival of patients with multiple myeloma in New Zealand.新西兰多发性骨髓瘤患者的总体生存率受年龄、性别、种族、社会经济剥夺和新型药物的影响。
Br J Haematol. 2020 Mar;188(5):692-700. doi: 10.1111/bjh.16238. Epub 2019 Oct 4.
2
Many Shades of Disparities in Myeloma Care.骨髓瘤治疗中差异的多种表现形式
Am Soc Clin Oncol Educ Book. 2019 Jan;39:519-529. doi: 10.1200/EDBK_238551. Epub 2019 May 17.
3
Mortality of lymphoma and myeloma in China, 2004-2017: an observational study.
Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants.儿童和成人罕见实体瘤的纵向自然史研究:前 200 名参与者的初步结果。
Cancer Res Commun. 2023 Dec 6;3(12):2468-2482. doi: 10.1158/2767-9764.CRC-23-0247.
4
Global disparities in patients with multiple myeloma: a rapid evidence assessment.全球多发性骨髓瘤患者的差异:快速证据评估。
Blood Cancer J. 2023 Jul 18;13(1):109. doi: 10.1038/s41408-023-00877-9.
5
Integration of clinical features and sociodemographic factors: a simplified prognostic model for patients with multiple myeloma based on a double-center retrospective analysis.临床特征与社会人口学因素的整合:基于双中心回顾性分析的多发性骨髓瘤患者简化预后模型
Am J Cancer Res. 2023 Mar 15;13(3):1038-1048. eCollection 2023.
6
The evolving diagnosis and treatment paradigms of multiple myeloma in China: 15 years' experience of 1256 patients in a national medical center.中国多发性骨髓瘤的诊治演变:15 年国家医学中心 1256 例患者的经验。
Cancer Med. 2023 Apr;12(8):9604-9614. doi: 10.1002/cam4.5737. Epub 2023 Feb 21.
7
Socioeconomic status-based survival disparities and nomogram prediction for patients with multiple myeloma: Results from American and Chinese populations.基于社会经济地位的多发性骨髓瘤患者生存差异及列线图预测:来自美国和中国人群的结果
Front Oncol. 2022 Aug 26;12:941714. doi: 10.3389/fonc.2022.941714. eCollection 2022.
8
Response and Survival Estimates of Patients With Plasma Cell Myeloma in a Resource-Constrained Setting Using Protocols From High-Income Countries: A Single-Center Experience From Sri Lanka.资源有限环境下采用高收入国家方案治疗浆细胞骨髓瘤患者的反应和生存估计:来自斯里兰卡的单中心经验。
JCO Glob Oncol. 2022 Jun;8:e2100352. doi: 10.1200/GO.21.00352.
9
Associations of Education Level With Survival Outcomes and Treatment Receipt in Patients With Gastric Adenocarcinoma.教育水平与胃腺癌患者生存结局和治疗接受情况的相关性。
Front Public Health. 2022 Jun 9;10:868416. doi: 10.3389/fpubh.2022.868416. eCollection 2022.
10
Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation.缺乏护理人员与接受自体干细胞移植的骨髓瘤患者的生存时间更短有关。
Leuk Lymphoma. 2022 Oct;63(10):2422-2427. doi: 10.1080/10428194.2022.2074993. Epub 2022 May 12.
中国 2004-2017 年淋巴瘤和骨髓瘤的死亡率:一项观察性研究。
J Hematol Oncol. 2019 Mar 4;12(1):22. doi: 10.1186/s13045-019-0706-9.
4
Cancer statistics, 2019.癌症统计数据,2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
5
Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials.多发性骨髓瘤的疾病和结局差异:探索种族/民族在合作组临床试验中的作用。
Blood Cancer J. 2018 Jul 6;8(7):67. doi: 10.1038/s41408-018-0102-7.
6
Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies.新型疗法时代新诊断多发性骨髓瘤老年患者的治疗不足
Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):219-224. doi: 10.1016/j.clml.2018.01.005. Epub 2018 Jan 31.
7
Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.自体移植治疗新诊断多发性骨髓瘤在新型诱导药物时代:系统评价和荟萃分析。
JAMA Oncol. 2018 Mar 1;4(3):343-350. doi: 10.1001/jamaoncol.2017.4600.
8
Patient education-level affects treatment allocation and prognosis in esophageal- and gastroesophageal junctional cancer in Sweden.在瑞典,患者的教育水平会影响食管癌和胃食管交界癌的治疗分配及预后。
Cancer Epidemiol. 2018 Feb;52:91-98. doi: 10.1016/j.canep.2017.12.008. Epub 2018 Jan 4.
9
A global comparison of the cost of patented cancer drugs in relation to global differences in wealth.专利抗癌药物成本与全球财富差异的全球比较。
Oncotarget. 2017 May 9;8(42):71548-71555. doi: 10.18632/oncotarget.17742. eCollection 2017 Sep 22.
10
Demographic and socioeconomic predictors of treatment delays, pathologic stage, and survival among patients with penile cancer: A report from the National Cancer Database.阴茎癌患者治疗延迟、病理分期及生存情况的人口统计学和社会经济预测因素:来自国家癌症数据库的报告
Urol Oncol. 2018 Jan;36(1):14.e17-14.e24. doi: 10.1016/j.urolonc.2017.09.014. Epub 2017 Oct 12.